Alma Gregory Sorensen
Known title: EVP, Chief Science OfficerCIK: 0001731883
Associated companies
Transaction History
| RDNT | ▼ Sell | Open Market | 9,554 | $591K | 3/19/2026 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,346 | $336K | 3/19/2026 | View on chart |
| RDNT | ▼ Sell | Open Market | 100 | $6K | 3/19/2026 | View on chart |
| RDNT | ▼ Sell | Gift | 7,000 | $0 | 3/19/2026 | View on chart |
| RDNT | ▼ Sell | Open Market | 800 | $50K | 3/18/2026 | View on chart |
| RDNT | ▼ Sell | Open Market | 14,200 | $882K | 3/18/2026 | View on chart |
| RDNT | ▼ Sell | Tax Withholding | 5,919 | $365K | 3/16/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 8,727 | $0 | 3/10/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 6,237 | $0 | 3/10/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 7,481 | $0 | 3/10/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 4,987 | $0 | 3/10/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 3,742 | $0 | 3/10/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 12,466 | $0 | 3/10/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 2,493 | $0 | 3/10/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 16,831 | $0 | 3/10/2026 | View on chart |
| RDNT | ▲ Buy | Grant | 16,533 | $0 | 3/3/2026 | View on chart |
| RDNT | ▼ Sell | Gift | 5,600 | $0 | 6/17/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 10,436 | $0 | 6/1/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 55,000 | $3.1M | 5/23/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 45,000 | $2.6M | 5/22/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 10,232 | $0 | 5/1/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 11,072 | $0 | 1/8/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $623K | 6/12/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,000 | $306K | 6/11/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 19,423 | $0 | 1/9/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News
RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.